On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death†

Douglas B. Kell* and Etheresia Pretorius*†

We have recently highlighted (and added to) the considerable evidence that blood can contain dormant bacteria. By definition, such bacteria may be resuscitated (and thus proliferate). This may occur under conditions that lead to or exacerbate chronic, inflammatory diseases that are normally considered to lack a microbial component. Bacterial cell wall components, such as the endotoxin lipopolysaccharide (LPS) of Gram-negative strains, are well known as potent inflammatory agents, but should normally be cleared. Thus, their continuing production and replenishment from dormant bacterial reservoirs provides an easy explanation for the continuing, low-grade inflammation (and inflammatory cytokine production) that is characteristic of many such diseases. Although experimental conditions and determinants have varied considerably between investigators, we summarise the evidence that in a great many circumstances LPS can play a central role in all of these processes, including in particular cell death processes that permit translocation between the gut, blood and other tissues. Such localised cell death processes might also contribute strongly to the specific diseases of interest. The bacterial requirement for free iron explains the strong co-existence in these diseases of iron dysregulation, LPS production, and inflammation. Overall this analysis provides an integrative picture, with significant predictive power, that is able to link these processes via the centrality of a dormant blood microbiome that can resuscitate and shed cell wall components.

Insight, innovation, integration

The Biological Insight of this manuscript is that while dormant bacteria, including those in blood, are normally unnoticed (as they are invisible to conventional methods of culture), they can by definition be resuscitated and then proliferate for at least a certain number of generations before possibly returning to a state of dormancy. This allows a continuing production and shedding of potent inflammatory agents such as the lipopolysaccharide (LPS) characteristic of the Gram-negative cell wall. Well-established pathways link LPS (sensu lato) to inflammatory cytokine production, and to cell death via apoptosis, programmed necrosis, and pyroptosis, with the accompanying microparticle formation known to occur with these cell death mechanisms. Cytokine-mediated cell death mechanisms that permit both (i) the translocation of bacteria between blood and other tissues, and (ii) localised proliferation leading to inflammation and cell death, are likely to be a major component of the various disease manifestations involved. One established requirement for bacterial resuscitation and proliferation comes from the need for available iron. The Technological Innovation is the use of advanced microscopy techniques to detect these dormant bacteria as well as microparticle formation. The Benefit of Integration comes (i) from bringing together these multiple biochemical elements (bacterial dormancy and resuscitation, LPS-induced inflammatory cytokine production, cytokine-induced cell death, cell-death-induced translocation, and localised cell death induced by LPS), and (ii) by showing their commonality, and the centrality of LPS, across a range of chronic, inflammatory diseases normally considered to lack a microbial component.

Introduction

Blood is normally considered a sterile environment in the sense of lacking active microbes, since any bacteraemia or sepsis is potentially extremely life-threatening. However, this does not exclude the presence in blood of dormant bacteria, that by definition are not growing but resist detection by standard culture techniques, yet are not ‘dead’ as they may be resuscitated.

† Paper 3 in the series “The dormant blood microbiome in chronic, inflammatory disease”.

* School of Chemistry and The Manchester Institute of Biotechnology, The University of Manchester, 131, Princess St, Manchester M1 7DN, Lancs, UK. E-mail: dbk@manchester.ac.uk; Web: http://dbkgroup.org/; Tel: +44 (0)161 306 4492
† Department of Physiology, Faculty of Health Sciences, University of Pretoria, Arcadia 0007, South Africa. E-mail: resia.pretorius@up.ac.za; Tel: +27 12 420 2864
and then proliferate. We have recently summarised the considerable evidence\textsuperscript{4,5} to the effect that human blood contains an authentic but dormant microbiome that can contribute significantly to a large variety of chronic inflammatory diseases, a set of diseases that is strikingly similar to those for which we had previously noted the presence of iron dysregulation\textsuperscript{6–10} and hypercoagulability.\textsuperscript{9}

Given the well-established facts (i) that microbial growth \textit{in vivo} is normally strongly limited by the (non-) availability of free iron (e.g. ref. 11–21), and (ii) that bacterial components such as lipopolysaccharide (LPS) are strongly inflammatory (e.g. ref. 22 and 23), such an analysis leads to the recognition that the iron-related inflammatory diseases also have a major microbial component involving the resuscitation of dormant organisms and their shedding of inflammatory molecules, and especially of cell wall components such as LPS (Fig. 1). LPS is commonly known as endotoxin, albeit that it is frequently shed, and we shall use this name interchangeably unless otherwise specified. Most work has been done with LPS from Gram-negative bacteria, but unless specified, we recognise that much of what we have to say should be taken to apply to inflammatory processes catalysed by cell wall components (such as lipoteichoic acids\textsuperscript{24}) from Gram-positive organisms, ultramicrobacteria,\textsuperscript{25} and potentially (though there seems to be relatively little work on this\textsuperscript{26–29}) from the cell envelopes of archaea. Also, though many of the ideas developed here very likely apply to them too, and there is a considerable literature, we shall not discuss viruses,\textsuperscript{30} nor mycoplasmas\textsuperscript{31–33} in much detail.

The earlier overviews\textsuperscript{4,5} recognised that the chief sources of the blood microbiome were likely to be via translocations of microbes from the gut and oral cavities, and although a number of the diseases discussed were neurodegenerative in nature, we did not look at the evidence (and mechanism) for the transport of cells from blood into tissues such as the CNS. A chief purpose of the present review is thus to take a systems approach, designed to bring together the evidence for the strong involvement of microbes and their inflammatory bacterial cell wall components in both the diseases themselves and their dynamics, and relating the known ability of LPS and related

---

**Fig. 1.** An overall illustration of the headline processes involved in chronic inflammation and disease aetiology mediated via the resuscitation of dormant microbes and the increased production and shedding of cell wall components.

---

**Perspective**

---

**Douglas Kell**

Douglas Kell is Research Professor in Bioanalytical Science at the University of Manchester, UK. His interests lie in systems biology, iron metabolism and dysregulation, microbial dormancy, cellular drug transporters, synthetic biology, e-science, chemometrics and cheminformatics. He was Director of the Manchester Centre for Integrative Systems Biology prior to a 5-year secondment (2008–2013) as Chief Executive of the UK Biotechnology and Biological Sciences Research Council. He is a Fellow of the Learned Society of Wales and of the American Association for the Advancement of Science, and was awarded a CBE for services to Science and Research in the New Year 2014 Honours list.

---

**Etheresia Pretorius**

Etheresia Pretorius is a Research Professor in the Department of Physiology, Faculty of Health Sciences at the University of Pretoria, South Africa. Her interests lie in the ultrastructure and regulation of the human coagulation system, and the role of iron metabolism and changes to the coagulation system due to inflammation. She is also Director of the Applied Morphology Research Centre of the University of Pretoria. She was chosen as the winner in 2011 of the African Union Kwame Nkrumah Scientific Awards Program: Women Scientist Regional Awards in the category Basic Science and Technology.
component to induce (mainly apoptotic) cell death. This turns out to be sufficient to explain many of the acute and chronic sequelae of the presence of microbes and their cell envelope products in mammals. An overview of the present article is given in the form of a mind map (Fig. 2). As background, we first discuss microbial dormancy, culturability and non-culturability.

**A dormant blood microbiome**

**Nature**

As foreshadowed in the introduction, we and others have summarised the rather extensive evidence that the presence of bacteria in blood is – perhaps unsurprisingly, given the assumption that blood is normally sterile – much commoner than is usually supposed, and we have pointed out that, in the usual absence of overt bacteraemia, such organisms are best considered as being in a dormant physiological state.

Dormancy is defined as a reversible non-replicating state, often of low metabolite activity. Leaving aside obviously specialised forms such as spores and seeds (‘constitutive dormancy’), in non-spore-forming bacteria it manifests typically as an inability of an individual cell to proliferate (e.g. to form a colony) under conditions normally considered adequate for cultivation, but where the cell is not operationally ‘dead’ in that it can revert to a state of ‘aliveness’ or ‘culturability’ via processes referred to as resuscitation. Thus, by definition, dormant cells are resuscitable, but this necessarily operational definition means that we can only tell that they were dormant, not that they are dormant. Indeed, the ability to undergo dormancy (as with pheromone production) is increasingly being recognised as an adaptive phenotypic trait (e.g. ref. 38–41). Ewald in particular (e.g. ref. 42–44) has stressed the evolutionary aspects of infectious diseases.

**Evidence**

The evidence for a dormant blood microbiome comes mainly from its direct assessment using culture-independent methods (although we know of Domingue’s resuscitation papers). Culture-independent methods include the detection of blood (or tissue) microbial macromolecules such as rDNA and the direct visualisation of cells using ultramicroscopic methods (e.g. ref. 5, 43, 45, 46, 60–64). In particular, it is recognised that dormant blood bacteria could ‘hide’ (or at least survive) not only in white cells (e.g. ref. 69) but also within the (more than 1000-fold more numerous) erythrocytes. The significance of this, of course, is the sheer numbers that may be involved. If only one in 50 000 erythrocytes (that are present in blood at ca. 5 × 10^12 mL⁻¹) each harboured just a single dormant bacterium, there would still be more than 10^5 mL⁻¹ (a number equivalent in urine to the threshold normally given for culturable cells in defining clinical bacteriuria).

Although there is evidence that a surprisingly large variety of bacteria can invade erythrocytes, we know next to nothing about how they enter and egress from such cells. Even whether the latter involves pore-forming toxins or haemolysins that may effect membrane destruction, is unclear.

**Origins, and translocation into blood**

We also rehearsed the considerable evidence that minor leakages from the gut microbiome (e.g. ref. 73–75), even if only a tiny fraction of the 10–100 trillion cells involved, whether via specialised structures such as M cells or more significant breaches in the gut epithelium (as can also occur in some cancers and stroke), are more than sufficient to provide a continuing inoculum to the bloodstream. Clearly the innate and adaptive immune system will normally remove those organisms threatening growth and noticeable bacteraemia, but this statement does not account for the fraction that become dormant and hide therefrom (whether geographically in cells and/or by losing their immunogenic potential, for instance by creating L-forms). While the dormant bacteria do seem mainly to be hidden inside cells, their inflammatory products may not be. In the blood, LPS is typically bound to an LPS binding protein (LBP) which is a glycoprotein with a molecular weight of some 58 kDa (452 amino acids) or to the lipoprotein ApoE that is protective against LPS. The ApoE4 polymorphism is of course well known as a genetic
locus favouring the development of Alzheimer’s disease (e.g. ref. 87–92).

'Concentrations' of LPS and LPS-binding protein in blood

Our central argument is that low grade inflammation is mainly effected via the continuing production and shedding of LPS (and similar molecules) as dormant bacteria periodically awaken, proliferate and produce LPS before returning to dormancy. If this is going to be true, it is instructive to determine how much LPS and related molecules are typically found in human blood under various conditions. The potential load of LPS in the alimentary canal is ~1 g.93 We note, of course, that (as with serum ferritin9) the basis of these assays used to estimate concentration is typically a binding reaction, whether to an antibody or (in the case of LPS) based on a Limulus amoebocyte lysate (or its recombinant factor C94). Thus these and other (e.g. ref. 95–97) assays typically measure the (thermodynamically active) free forms, while the total amounts may be very much greater if (as with LPS) they are mainly bound to LBP or ApoE of HDL/cholesterol, or even monocyte surfaces.98 Indeed, given that HDL–cholesterol is capable of sequestering LPS99 (and lipoteichoic acid100), it is not surprising that there is considerable evidence that HDL–cholesterol is protective against sepsis and sepsis-related death.83,101–107 showing further the importance of free LPS levels in disease prognosis.

This said, it is important to point out that if a substance is hydrophobic, i.e. poorly water-soluble, and its targets are hydrophobic (i.e. insoluble) as well, its measured potency also depends on the concentration of the hydrophobic elements containing the target (or otherwise).108,109 In such circumstances, it is arguably better to speak of functional concentrations in terms of nmol per nmol target or similar, rather than in concentration terms (e.g. nM). In a similar vein, when considering properties such as cell death, what matters is the distribution of ligands between targets and the fraction of cells that die. In other words, if an added toxic molecule kills a cell (i.e. irreversibly) then this is a quantised property of the molecule, and again ‘concentrations’ are not an entirely meaningful manner with which to describe the toxic stimulus.3,110,111

Our main purpose here, though, is comparative, and aimed at obtaining a feel for the typical concentrations in health and disease, and those that are used in research studies. Note that as well as coming from infections, LPS is a common component of dust.112 Thus, reported LPS ‘concentrations’ in healthy subjects seem to be of the order of 10–15 ng L⁻¹, while those of LBP are roughly 1 000 000 times greater at 5–15 mg L⁻¹ (with both values increasing during sepsis) (Tables 1 and 2). LPS challenges of 5–100 µg per patient are commonly administered as experimental challenges and seen as ‘safe’.112 The larger volume, if distributed in 5 L of blood (a typical human value) equates to 20 000 ng L⁻¹, which is obviously much higher than those free amounts typically measured even in sepsis. In terms of relating LPS to microbial biomass (see ref. 113),

<table>
<thead>
<tr>
<th>Tissue type</th>
<th>LBP in disease (mg L⁻¹)</th>
<th>LBP in control (mg L⁻¹)</th>
<th>Place</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial gastrointestinal infections</td>
<td>28.5 ± 16.5</td>
<td>—</td>
<td>Serum 122</td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease (CD) and ulcerative colitis (UC)</td>
<td>57.11 (49.4–65.8)</td>
<td>50.01 (37.1–63.9)</td>
<td>Plasma 123</td>
<td></td>
</tr>
<tr>
<td>Diabetes type 2</td>
<td>19.78 ± 6.40</td>
<td>20.53 ± 6.99</td>
<td>Serum 124</td>
<td></td>
</tr>
<tr>
<td>Endocarditis</td>
<td>Median 33.41</td>
<td>Median 5.61</td>
<td>Serum 125</td>
<td></td>
</tr>
<tr>
<td>Infectious endocarditis</td>
<td>Median 6.67</td>
<td>—</td>
<td>Serum 125</td>
<td></td>
</tr>
<tr>
<td>Noninfectious heart valve diseases</td>
<td>52.7 (45.4–64.6)</td>
<td>39.1 (32.1–43.7)</td>
<td>Serum 123</td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>Median 33.41</td>
<td>Median 5.61</td>
<td>Serum 125</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>7.11 (5.85–8.74)</td>
<td>7.18 (5.42–9.15)</td>
<td>Serum 83</td>
<td></td>
</tr>
<tr>
<td>Obese</td>
<td>5.90 (5.09–7.67)</td>
<td>7.75 (6.35–9.47)</td>
<td>Serum 128</td>
<td></td>
</tr>
<tr>
<td>Overweight</td>
<td>5.90 (5.09–7.67)</td>
<td>7.29 (5.96–8.78)</td>
<td>Serum 128</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>6.82 (5.48–8.40)</td>
<td>8.02 (6.63–9.82)</td>
<td>Serum 128</td>
<td></td>
</tr>
<tr>
<td>Obesity, T2D and metabolic syndrome</td>
<td>Median 36.6</td>
<td>Median 7.8</td>
<td>Plasma 130</td>
<td></td>
</tr>
<tr>
<td>Liver Hepatocytes</td>
<td>5 to 15</td>
<td>—</td>
<td>Cells 127</td>
<td></td>
</tr>
<tr>
<td>Hepatic macrophages</td>
<td>—</td>
<td>—</td>
<td>Cells 127</td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection in childhood</td>
<td>&gt; 43.23</td>
<td>—</td>
<td>Serum 129</td>
<td></td>
</tr>
<tr>
<td>Sepsis Sepsis/septic shock LBP concentration</td>
<td>46.2 (3.74–155)</td>
<td>7.94</td>
<td>Serum 127</td>
<td></td>
</tr>
<tr>
<td>at onset of severe sepsis</td>
<td>—</td>
<td>—</td>
<td>Serum 127</td>
<td></td>
</tr>
<tr>
<td>Sepsis in neonates</td>
<td>Median 36.6</td>
<td>Median 7.8</td>
<td>Plasma 130</td>
<td></td>
</tr>
<tr>
<td>Late-onset neonatal sepsis (LONS)</td>
<td>17.5</td>
<td>Unstated</td>
<td>Plasma 131</td>
<td></td>
</tr>
<tr>
<td>Gram +ve or Gram –ve sepsis</td>
<td>216</td>
<td>16</td>
<td>Plasma 132</td>
<td></td>
</tr>
<tr>
<td>(Higher in survivors)</td>
<td>31</td>
<td>4</td>
<td>Plasma 133</td>
<td></td>
</tr>
<tr>
<td>Septic shock tests</td>
<td>200</td>
<td>5–15</td>
<td>Unstated 134</td>
<td></td>
</tr>
<tr>
<td>Non-survivors 121 vs. 77 at 48 h</td>
<td>116–132 baseline</td>
<td>8–15</td>
<td>Serum 135</td>
<td></td>
</tr>
<tr>
<td>Remained much higher in non-survivors</td>
<td>34–55</td>
<td>—</td>
<td>Serum 136</td>
<td></td>
</tr>
</tbody>
</table>
A dormant tissue microbiome

Our previous reviews\(^4,5\) (and many other works, e.g. those summarised in ref. 43, 62, 64 and 144) outlined in some detail the fact that many known infectious agents can enter cells and persist intracellularly, and those discussions are not repeated in detail here. Indeed, the very existence of eukaryotes is considered to be based on the intracellular uptake of prokaryotes to form structures such as mitochondria,\(^{145}\) and there is increasing evidence for dinitrogen fixation by endosymbionts in plant leaf cells (e.g. ref. 146 and 147). Regarding human tissue, as Nash and colleagues put it,\(^{144}\) “the blood is the most effective vehicle of all for the spread of microbes through the body. After entering the blood they can be transported within a minute or two to a vascular bed in any part of the body. In small vessel such as capillaries and sinuses where blood flows slowly, there is an opportunity for the microorganism to be arrested and to establish infection in neighbouring tissues.” (The same holds true, of course, for circulating tumour cells and their role in metastasis.) Later we shall look at this translocation from blood to tissues in more detail. However, we first mention an example that we did not deal with previously in much detail, viz. *E. coli*-based cystitis.

**E. coli**-based cystitis

Cystitis (inflammation of the bladder) is commonly caused by urinary tract infection, typically by *E. coli,\(^{48,149}\) and...
especially in women. It can also lead to bacteraemia. A particular point of present interest regarding dormancy is the fact that a high percentage of cystitis patients suffer reinfection, that is often clearly from the same strains that caused the original infection. This has led to the recognition in bladder epithelial cells of so-called ‘quiescent intracellular reservoirs’ of dormant cells that can resuscitate. Because one cannot determine these things in humans in vivo, it is not known precisely how they enter such cells after binding to appropriate receptors such as uroplakins, but it is presumed that as with many other cells where it is better understood this occurs via endocytosis of some kind.

Separating the blood from certain tissues are physical barriers such as the blood–brain, blood–retina and blood–testis barriers, consisting of layers of epithelial cells with especially tight junction. They are of notable significance to drug transporters as well. It is of particular interest that even here we can find that these barriers are (or must be) breached from time to time, as dormant microbes can be found even in the CNS. Possible means of resuscitation are discussed below and elsewhere.

A dormant CNS microbiome

As one might suppose, the CNS differs little from other tissues with regard to the possibility that dormant microbes may persist there, occasionally ‘waking up’ to cause trouble. Three examples, as they pertain to the aetiology of Alzheimer’s disease (and presumably other dementias) are represented by Chlamydia pneumoniae (as stressed by Balin and colleagues, e.g. ref. 176–185), by herpes simplex virus (as highlighted by Itzhaki and elsewhere.4 As one might suppose, the CNS differs little from other tissues with regard to the possibility that dormant microbes may persist there, occasionally ‘waking up’ to cause trouble. Three examples, as they pertain to the aetiology of Alzheimer’s disease (and presumably other dementias) are represented by Chlamydia pneumoniae (as stressed by Balin and colleagues, e.g. ref. 176–185), by herpes simplex virus (as highlighted by Itzhaki and elsewhere.4

A high-level overview of the effects of LPS in sepsis, septic shock and SIRS

Although our focus here is more on chronic inflammatory states induced by dormant and resuscitating bacteria, it is instructive first to consider events that occur in the more extreme and life-threatening cases of sepsis, septic shock, and the systemic inflammatory response syndrome (SIRS). While these are commonly observed in the Intensive Therapy Unit as a result of an initial infection (hence the term ‘sepsis’), their typical treatment there with broad spectrum antibiotics means that proliferating microbes are rare or absent, and it is their products such as LPS that are then the main problem. Specifically, although these are responsible for invoking the innate immune response that triggers cells to attack and dispose of the invading microbes, an overstimulation of these activities leads to the life-threatening ‘cytokine storms’ that are the proximate causes of, and reflect, endotoxic or septic shock or SIRS (e.g. ref. 7 and 239–247).

It is worth rehearsing the definitions help discriminate sepsis from its sequelae. Thus, sepsis has been defined as “the presence (probable or documented) of infection together with systemic manifestations of infection”, while severe sepsis is defined as sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion. Septic shock is “sepsis-induced hypotension persisting despite adequate fluid resuscitation”. SIRS refers to “the systemic inflammatory response to a variety of severe clinical insults” (infectious or otherwise). It usually involves two or more of the following criteria: (i) temperature > 38 °C or < 36 °C; (ii) heart rate > 90 beats per m; (iii) respiratory rate > 20 breaths per m or PaCO₂ < 32 mm Hg; (iv) WBC count < 12,000 µL⁻¹ or > 4000 µL⁻¹ or (v) > 10% immature neutrophil forms (i.e., “bands”). The chief point about recognising and using SIRS instead of ‘sepsis’ is, of course, that it does not rely on the presence of observable (or culturable) microbes (and it can anyway be caused by traumas lacking an immediate microbial component). A Venn diagram (redrawn from ref. 254) illustrates the main ideas (Fig. 3).

Clearly any increases in microbial cell numbers increase the likelihood of LPS production and shedding that leads to the cytokine storm. Thus, the progression of the microbial variant in unfavourable cases goes roughly from left to right in Fig. 4, as infection → bacteraemia → LPS → sepsis → septic shock → SIRS → multiple organ failure (MOF/MODS) → death. Mortality rates from sepsis/SIRS are extremely high (30–70% in intensive care units), and dependent on age. Note too that antibiotics can themselves promote shedding of LPS from dying bacteria (e.g. ref. 118 and 256–265), especially from spirochetes such as Borrelia burgdorferi, leading to a Jarisch–Herxheimer (JH) reaction. The JH reaction can be mitigated by antibodies to TNF-α. Importantly, this continual shedding of LPS is a normal property of growing Gram-negative bacteria, especially in...
media such as those containing serum that are inimical to their growth. This has obvious implications. Even if one survives septic shock, there are other sequelae, such as long-term cognitive impairment, cardiovascular and other complications that may reflect or contribute to symptoms seen under more chronic conditions. Indeed, there are a great many comorbidities between various diseases with a microbial component.

Clearly, LPS plays a central role in the development of inflammation. We therefore spend time in the next paragraphs to discuss the role of LPS in the cellular inflammatory processes.

Positive feedback and amplification in integrative and systems biology

The first point to make here is a general one about how various kinds of kinetic schemes or network topologies can amplify biochemical signals. For a single enzyme, if its product or any other molecule is an uncompetitive inhibitor that binds only to the enzyme–substrate complex, a small amount of this can lead to a very large increase in a substrate concentration. This serves to explain both the peculiar effectiveness of glyphosate as a herbicide, and the extreme rarity of uncompetitive inhibition in natural systems. One type of network-based amplification, that is familiar in signalling cascades, is one in which a signalling activity such as a kinase changes the activity of another kinase, and so on. Here, as well as amplification, the cascade is partly about serving as a suitable delay loop, as clearly variations in amino acid sequence can and do have major effects on the activities of individual proteins such that the cascade would otherwise seem unnecessary. A second kind of amplification, known as ultrasensitivity, comes from a structure in which an effector stimulates by covalent modification (e.g. phosphorylation) of an enzyme catalysing a particular reaction, while simultaneously inhibiting a second enzyme (e.g. a phosphatase) catalysing the removal of the covalent modification. This leads to very large changes in flux and network behaviour as the concentration of the effector passes a threshold. Similarly, pulsatile or oscillatory signals can be much more effective for the same ‘average’ concentration. Thus, a variety of network motifs can provide “sniffers, buzzers, toggles and blinkers”. And most of all, although other behaviours are possible, a variety of simple systems with positive feedback can amplify a very small signal into a much larger one (Fig. 5). This can typically occur in inflammatory systems where molecules whose production is induced by LPS, such as IL-1β or TNF-α (Fig. 6) can stimulate their own synthesis or effect crosstalk (e.g. IL-1 induced TNF-α).

A second major area where an effector can appear to amplify a small stimulus, or have a large effect, is when it interacts with multiple targets simultaneously (in drug discovery this is known as polypharmacology). This need actually follows from the principles of systems biology as encapsulated in metabolic control analysis, where mediators that modify only one target can rarely be expected to have much effect. As we shall see, LPS qualifies here too, as it stimulates a great many proinflammatory and proapoptotic pathways, including those necessary for its translocation in both free and bacterial cell-associated forms.
Thus we shall see that LPS is likely to serve as a major nexus in inflammation in general and that induced by microbes in particular.

Structure and function of LPS

An overall ‘cartoon’-type structure of typical LPS molecules is given in Fig. 7A based on. They consist of an inner lipid A core and a number of branched polysaccharide chains (e.g. ref. 302–307), terminating in those that determine the strain’s serology via the O-antigen. The biosynthesis is discussed by Wang and Quinn. According to the comprehensive LIPID-MAPS classification, LPS is a saccharolipid glycan. The lipid A core is significantly the most inflammatory part of the molecule, with typically two N-acetylgalcosamine residues attached to a 2-keto-3-deoxy-D-manno-octulosonic acid (Kdo) disaccharide (Fig. 7B). Bacteria lacking the outer O-antigen chains are either fixed or outside the control of the experimenter; they typically discriminate parameters from variables. Parameters that in a typical network of this type, a systems approach involving the mathematical form of the equations describing each step, and their parametrisation, also involving the running of the model, typically as a set of coupled ordinary differential equations, using suitable software (e.g. ref. 313–315). Note too that in a typical network of this type, a systems approach typically discriminates parameters from variables. Parameters are either fixed or outside the control of the experimenter; they typically include the unchanging concentrations of substances involved in flux-generating steps, as well as kinetic constants such as $K_m$ and $k_{cat}$. By contrast, variables are those things that vary during an experiment, typically involving concentrations of intermediary substances and fluxes through pathways towards ‘exit’ variables. Thus, figures such as those in Fig. 1, while accurate in the sense of illustrating flows of information, are misleading because they are at once both static and qualitative. While we can and shall point to many papers that show clearly that “LPS can cause inflammation (or apoptosis)”, such a statement too is less than complete. This is because individual papers rarely if ever state, use or vary systematically a number of parameters that are known to have a huge impact on cell fate. These include:

- The exact type of LPS (even though some, especially their lipid A component, are known to be much more immunogenic or inflammatory than are others – see e.g. ref. 306, 309 and 316–324 and later)
- The rather variable amount of LPS added, whether the assay is for cytokine production (Table 3) or ‘viability’ (Table 4)
- The nature of the host (human or rodent, that respond differently, or in vitro)
- Whether the LPS is added in a bolus or a dynamic manner (this matters a lot)
- Whether measurements are done in single cells or as an ensemble, and or quasi-continuously; this matters because much evidence in the NF-κB system and other related systems shows that it is the nature and dynamics of the oscillations that determines which genes are transcribed and with which kinetics, as well as cell fate, and not just say an NF-κB concentration at a particular time. Thus knowledge of single-cell behaviour is vital (also in pharmaceutical drug uptake).
- Which other substances, conditions or parameters have been co-varied or even recorded, and whether they themselves are known to modify the effect of LPS alone. One example is ATP, which activates the purinergic PX27 receptors and increases massively the extent of cell death. Another is acidosis.

LPS as a stimulant of inflammatory cytokine production: cellular mechanisms

While only partly consistent with the ‘danger theory’ of the immune response, and more obviously stemming from the ideas of Janeway, LPS is recognised as a major ‘pathogen-associated molecular pattern’ or PAMP that triggers the body’s innate immune response to pathogens (e.g. ref. 367). In addition, cells release damage-associated molecular pattern molecules (DAMPs) as signals that alert the innate immune system to unexpected cell death and to microbial invasion. It is now very well established that a chief means by which LPS excites an inflammatory innate immune response is by binding to the toll-like receptor 4 (TLR4). Typically, the LPS is bound in...
blood to LBP, and the LPS is ferried to the TLR4 receptor via a CD14 co-receptor (which also links innate immunity with Alzheimer’s disease\(^ {374–377} \)). This binding of LPS to TLR4 in turn activates the production of a variety of pro-inflammatory cytokines.\(^ {378–381} \) The extent of cytokine activation reflects in part the strength of binding to CD14/TLR4.\(^ {320} \) These inflammatory cytokines are induced via a set of canonical pathways illustrated in Fig. 8, with the transcription factor NF-κB playing a prominent role.\(^ {382–385} \) As is also well known (and see below), NF-κB is normally held inactive in the cytoplasm by being bound to an inhibitor IκB protein, and the means by which extracellular signals such as LPS are transduced involve a series of kinases, one of which (IKK) in particular phosphorylates the IκB and thereby releases the NF-κB that can translocate to the nucleus to turn on a large variety of other genes, including in particular TNF-α and IL-6.\(^ {386} \) There is also a ‘non-canonical’ inflammasome LPS activation pathway independent of TLR4,\(^ {387–389} \) that occurs at higher external concentrations of LPS,\(^ {23,390} \) comes into play when the LPS is internalised, and involves (via p38 MAP kinase and intracellular LPS) the activation and secretion of cytokines such as IL-1β (Fig. 9) and also TNF-α.

**Muropeptides and host signalling**

A more recent recognition is that as well as lipid A, shorter bacterial cell-wall derived muropeptides also have a significant role in innate immunity (e.g. ref. 392–405; they act synergistically...
Table 3  Some examples of LPS administered to cells (primary or permanent cell culture or in vivo) or animals and its effect on interleukin and TNF-α production

<table>
<thead>
<tr>
<th>Cell type/animal origin</th>
<th>Cell name</th>
<th>LPS concn administered to cells/animals</th>
<th>LPS type</th>
<th>Measurement: interleukin and TNF-α production</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peritoneal mouse macrophages</td>
<td>Raw 264.7 mouse macrophages</td>
<td>100 ng mL⁻¹</td>
<td><em>Escherichia coli</em> O55:B5</td>
<td>Increased IL-6 production</td>
<td>338</td>
</tr>
<tr>
<td>C57BL/6 mice</td>
<td>Primary microglial cultures</td>
<td>100 ng mL⁻¹</td>
<td><em>E. coli</em> O26:B6</td>
<td>Massive increase in IL-1 but when purinergic receptor activated</td>
<td>335</td>
</tr>
<tr>
<td>IL-1Ra knockout (KO) and wild-type (WT) mice</td>
<td>Peritoneal macrophages (primary cultures)</td>
<td>10 μg mL⁻¹</td>
<td><em>Aggregatibacter actinomycetemcomitans</em> LPS</td>
<td>Increased production of IL-12, IL-1β, TNF-α and IL-6 in IL-1Ra KO mice, compared with the levels in WT mice</td>
<td>339</td>
</tr>
<tr>
<td>Mouse alveolar macrophages</td>
<td>MH-S cell lines</td>
<td>100 ng mL⁻¹</td>
<td>Sigma LPS type not stated</td>
<td>LPS stimulated overproduction of TNF-α and IL-10</td>
<td>340</td>
</tr>
<tr>
<td>C57BL/6 mouse</td>
<td>Primary macrophages</td>
<td>1 μg mL⁻¹</td>
<td><em>E. coli</em> O26:B6</td>
<td>Massive increase in IL-1β but not IL-6</td>
<td>341</td>
</tr>
<tr>
<td>Mouse microglia</td>
<td>BV2 microglia</td>
<td>100 ng mL⁻¹</td>
<td><em>E. coli</em> O55:B5</td>
<td>LPS-stimulation induces the expression of inducible NOS (iNOS) and COX-2</td>
<td>342</td>
</tr>
<tr>
<td>Intact mice (ob/ob), or C57BL/6 with diet-induced obesity</td>
<td>Primary cultures</td>
<td>5 μg or 100 μg kg⁻¹</td>
<td><em>E. coli</em> O127:B8</td>
<td>Massive increases in IL-1β, IL-6 and IL-10</td>
<td>238</td>
</tr>
<tr>
<td>J774.A1 macrophages</td>
<td>Primary cultures</td>
<td>10 μg mL⁻¹</td>
<td>Not stated, but was <em>E. coli</em> O26:B6</td>
<td>Huge increase in IL-1β production</td>
<td>343</td>
</tr>
<tr>
<td>Rat origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sprague-Dawley rats hippocampal brain slices</td>
<td>Serum level measurement</td>
<td>100 μg per rat, ip</td>
<td>Not stated</td>
<td>Increased IL-6 and TNF-α production</td>
<td>344</td>
</tr>
<tr>
<td>Sprague-Dawley rats hippocampal brain slices</td>
<td>Primary culture</td>
<td>10 μg mL⁻¹</td>
<td><em>E. coli</em> O55:B5</td>
<td>Significant increased concentration of TNF-α and IL-1β</td>
<td>345</td>
</tr>
<tr>
<td>Human origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human bone marrow aspirates</td>
<td>Bone marrow mesenchymal stem cell primary cultures</td>
<td>0 to 10 μg mL⁻¹</td>
<td><em>Porphyromonas gingivalis</em> LPS</td>
<td>IL-6 production independent of the LPS dosage</td>
<td>346</td>
</tr>
<tr>
<td>Peripheral blood mononuclear cells</td>
<td>Primary culture white blood cells</td>
<td>0.1, 1 or 100 ng mL⁻¹</td>
<td>Not stated</td>
<td>IL-6 and TNF-α were both strongly upregulated</td>
<td>347</td>
</tr>
<tr>
<td>HepG2</td>
<td>Hepatoma cell line</td>
<td>0.1, 1 or 100 ng mL⁻¹</td>
<td>Not stated</td>
<td>Slight inhibition of TNF-α</td>
<td>347</td>
</tr>
<tr>
<td>Peripheral blood mononuclear cells (PBMC) (from healthy and type 2 diabetes individuals (T2D)) Nasal polypfibroblasts</td>
<td>Primary culture white blood cells</td>
<td>2 and 0.2 ng mL⁻¹</td>
<td>TLR4 ligands LPS</td>
<td>With low LPS dose the T2D cohort exhibited enhanced IL-1β relative to healthy cells</td>
<td>348</td>
</tr>
<tr>
<td>Other animal origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Airway neutrophilia was induced in horses by inhalation of LPS</td>
<td>Animal model</td>
<td>1 mg mL⁻¹ per horse</td>
<td>Sigma LPS type not stated</td>
<td>Significant increased concentration of IL-6 and TNF-α</td>
<td>350</td>
</tr>
</tbody>
</table>
with LPS, probably because they also interact with the NF-kB pathway, via the RICK/Rip2/CARDIAK kinase. It is of particular interest in the context of bacterial dormancy that such muropeptides seem to be part of the ‘wake-up’ activity of the bacterial Rpf protein and other bacterial resuscitation systems.

**Table 4** Some examples of LPS administered to cells (primary or permanent cell culture or *in vivo*) and its effect on cell viability

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Cell name</th>
<th>LPS conc (ng mL⁻¹)</th>
<th>LPS type</th>
<th>Viability assay</th>
<th>Viability %</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat origin</td>
<td>Rat duodenum Epithelial cells</td>
<td>0.75–3 mg kg⁻¹ i.v. or 3–12 mg kg⁻¹ p.o.</td>
<td><em>H. pylori</em> LPS</td>
<td>MTT</td>
<td>60%</td>
<td>351</td>
</tr>
<tr>
<td>Rat myocytes</td>
<td>NR8383</td>
<td>25–10 000 (most 100)</td>
<td>Unstated</td>
<td>Apoptosis</td>
<td>80%</td>
<td>352</td>
</tr>
<tr>
<td>Alveolar macrophages</td>
<td></td>
<td>10</td>
<td>Unstated</td>
<td>LDH and Hoechst/PI</td>
<td>90% without particulates</td>
<td>353</td>
</tr>
<tr>
<td>Myocardial myocytes</td>
<td>H9c2</td>
<td>1000</td>
<td>Unstated</td>
<td>MT, LDH, TUNEL, JC-1</td>
<td>85%</td>
<td>354</td>
</tr>
<tr>
<td>Myocardial myocytes</td>
<td>H9c2</td>
<td>20 000</td>
<td>Unstated</td>
<td>MT</td>
<td>65%</td>
<td>355</td>
</tr>
<tr>
<td>Mouse origin</td>
<td>C57BL/6 mice Primary microglial cultures</td>
<td>100</td>
<td><em>E. coli</em> O26:B6</td>
<td>LDH release</td>
<td>~10% in presence of ATP</td>
<td>356</td>
</tr>
<tr>
<td>Osteoblast</td>
<td>MC3T3-E1</td>
<td>10 100 1000</td>
<td><em>E. coli</em> O55:B5</td>
<td>MTT</td>
<td>70%</td>
<td>357</td>
</tr>
<tr>
<td>Mouse macrophages</td>
<td>RAW 264.7</td>
<td>100</td>
<td>Unstated</td>
<td>MTT</td>
<td>Not stated; increased apoptosis</td>
<td>358</td>
</tr>
<tr>
<td>Macrophages</td>
<td>BMDM</td>
<td>100 (6 h)</td>
<td>Unstated</td>
<td>DNA fragmentation</td>
<td>~60%</td>
<td>359</td>
</tr>
<tr>
<td>Human origin</td>
<td>Pulmonary epithelia</td>
<td>A549</td>
<td>Unstated Sigma</td>
<td>Unstated kit</td>
<td>60–70%</td>
<td>359</td>
</tr>
<tr>
<td>Human PBMC</td>
<td>PBMC</td>
<td>0.01–3</td>
<td><em>E. coli</em> unstated</td>
<td>None – only IL-8 and ROS</td>
<td>360</td>
<td></td>
</tr>
<tr>
<td>Microglial</td>
<td>BV2</td>
<td>10 000–30 000</td>
<td>Unstated</td>
<td>MTT and trypan blue</td>
<td>~60%</td>
<td>361</td>
</tr>
<tr>
<td>Vascular human endothelia</td>
<td>HUVECs</td>
<td>500</td>
<td>Unstated</td>
<td>Annexin</td>
<td>80%</td>
<td>362</td>
</tr>
<tr>
<td>Dopaminergic</td>
<td>SH-SY5Y</td>
<td>100</td>
<td><em>E. coli</em> O127:B8</td>
<td>MTT</td>
<td>Unclear</td>
<td>363</td>
</tr>
</tbody>
</table>

**Fig. 8** The LPS-mediated cellular production of inflammatory cytokines. Canonical pathway of LPS-mediated release and nuclear translocation of NF-κB (based on ref. 379).

**Fig. 9** The intracellular LPS-mediated activation of caspase-1 leading to IL-1β production (after ref. 391).

**LPS induction of apoptotic, programmed necrotic and pyroptotic cell death**

A particularly important inflammatory cytokine whose secretion is induced by NF-κB (and also by p38 MAP kinase) is...
TNF-α (e.g. ref. 411–414). This too is inflammatory and itself induces further changes in NF-κB expression. The same is true for IL-1β. In particular, these inflammatory cytokines can lead to apoptotic cell death (e.g. ref. 343 and 358). As we shall see, however, and as presaged in Tables 3 and 4, it is quite difficult to establish precisely what is going on in many cases, as individual studies tend to study a restricted set of pathways and individual players, be they NF-κB, p38, IL-1β or IL-6. It would not in our view be completely unfair to describe a lot of these studies collectively as ‘a bit of a mess’. Taking NF-κB as a canonical example (though the same is true for p38415), what are ostensibly the same kinds of signal can lead to dramatically different cell fates, e.g. proliferation vs. apoptosis416–424 depending on the conditions. What this is telling us, of course, since these processes are considered largely deterministic, is that we are not measuring or controlling all of the relevant factors (see also Table 3), and in great measure these studies are largely qualitative in nature. Here our purposes are thus simply to recognise that the genes induced or repressed via transcription factors such as NF-κB can be pro- or anti-apoptotic, and which ones are activated depend on all prevailing conditions.

As well as apoptosis, there is a less tightly (but partly) regulated form of cell death known as ‘programmed necrosis’ or ‘necroptosis’,425–437 that may be induced by inflammatory ligands such as TNF, especially during infection, and that sometimes also involve NF-κB. Another important mode of cell death induced by related stimuli is pyroptosis438–450 (that involves the caspase 1-dependent production of IL-1β). Ferroptosis451,452 is a cell death mechanism that stresses the importance of unliganded iron (see also ref. 6, 7, 453 and 454). Although the stimulus in each of these cases is nominally the same (LPS of some kind) there are presumably pre-existing conditions that differ and thereby determine precisely the kind of cell death that ensues. However, we do not discuss the emerging differences in their molecular details nor taxonomy here, since the important thing for the present arguments is simply that the cells die, disappear, and thereby leave gaps where once they lived.

### LPS as a stimulant of coagulation and thrombosis

As we recently reviewed,9 a hallmark of many chronic, inflammatory diseases is the fact that they simultaneously exhibit both hypercoagulability and hypofibrinolysis. While a great many biochemicals can influence both the kinetics and end-product structures of the clotting process, and we previously highlighted unliganded iron8,10,455–458 and the fibrin concentration itself,9 we can hardly avoid noting that LPS itself is a strong procoagulant.459–461 How direct some of these mechanisms are seems not to have been established, though certainly LPS can bind to erythrocyte membranes.464,465 Given that promiscuity correlates with hydrophobicity (e.g. ref. 173 and 466–469), it is not surprising that the very hydrophobic LPS can potentially interact with a great many (lipo)proteins; its ability to convert prions to their more toxic PrPSc form470 is a pertinent case in point.

### The role of microparticles and LPS

We wish, however, to spend some time on the possible involvement of LPS in microparticle formation. Microparticle formation is typically via apoptosis and the related pathways described above.471–477 Such microparticle formation is prominently associated with inflammatory conditions. Microparticles have also been associated with proinflammatory effects and also with autoimmune processes, and they are thought to be a source of autoantigenic nuclear material, which can form immune complexes.475 Various cells such as platelets, lymphocytes, endothelial cells, erythrocytes and monocytes do release surface-derived microparticles476 and these microparticles are seen as multi-purpose carriers.477 They carry proteins, lipids and nucleic acids, and play a fundamental role in the pathogenesis of thrombosis and are known to modulate the properties of target cells.478 Microparticles from erythrocytes also carry heme and these heme-laden microparticles have a physiopathological impact on the rest of the haematological system.479 Microparticles also frequently elicit an immune response.480–483

As microparticles are known to be present in many inflammatory diseases,8,478,484–487 they might therefore develop via an
external or internal stimulus on cells (e.g. erythrocytes and platelets), and here we suggest that the stimulus might be LPS. While pure lipid systems are not always good membrane mimics,\textsuperscript{172–174} LPS has been shown to insert spontaneously into lipid bilayers, and this insertion can lead to membrane breakdown.\textsuperscript{480,488,489} This insertion capability has also been demonstrated in lipid raft models.\textsuperscript{490} Given that we have recently shown that bacteria can hide inside erythrocytes, shedding of LPS may thus occur within the cells (as well as obviously outside the cells, where “free” bacteria may shed LPS). There is considerable literature that suggests that LPS can be a cause of apoptosis etc, so LPS shed from internalized cellular bacteria may also trigger apoptotic pathways from within the cells (via caspase-11, caspase-4 and IL-1β pathways), resulting in microparticle formation. This eventually stimulates the processes of coagulation and thrombosis already known to be associated with microparticle presence in inflammatory conditions.\textsuperscript{491,492} An example of this is shown in Fig. 11A and B, where microparticle formation in thrombo-embolic ischemic stroke is seen associated with both hyperactivated platelets and damaged erythrocytes, together with the presence of bacteria.

The sequelae of intestinal inflammation and LPS-induced apoptosis, necroptosis and pyroptosis include epithelial permeabilisation

It is clear that as the concentration(s) or activities of LPS, inflammatory cytokines and other mediating factors increase, cell death is an inevitable consequence.\textsuperscript{425,493–495} While, as mentioned above, there is almost certainly a continuing small leakage of microbes from the gut\textsuperscript{496} (known as the ‘leaky gut’ hypothesis), it is evident that a variety of conditions, that we may loosely refer to as ‘stress’ can increase this considerably (e.g. ref. 73, 78 and 497–505). Bacterial sepsis itself is one such stress,\textsuperscript{506} and interestingly there is now a burgeoning literature to the effect that the immunodeficiency seen in HIV/AIDS patients may actually be caused by gut-derived LPS causing hyperactivation (then death) of CD4\textsuperscript{+} cells (e.g. ref. 138 and 507–509). There does not seem to be a major genetic contribution to leaky gut.\textsuperscript{510} Although many of the same signalling pathways are involved, the extent to which this is mediated \textit{via} LPS is not yet clear, albeit LPS itself can indeed disrupt tight junctions and increase intestinal permeability.\textsuperscript{511–516} Overall, these kinds of endothelial dysfunction clearly lead to increased leakiness or permeabilisation\textsuperscript{430} (Fig. 12).

Localised microbial proliferation, inflammation and cell death as a cause of specific diseases

We have here sought to provide a rather general explanation for the role of LPS-induced chronic inflammation in a variety of different diseases, with the ‘continuing’ element driven by the resuscitation of a resident blood and tissue microbiome. However, it is obvious that while all these diseases are inflammatory (and have been linked to microbes\textsuperscript{4,5} and/or LPS (Fig. 2), diseases such as Alzheimer’s, Parkinson’s, atherosclerosis and rheumatoid arthritis obviously occur – or one might better say manifest – in largely different tissue or tissue subtypes. Thus, the disappearance of cells from the CNS can manifest as Parkinson’s disease if in the dopaminergic neurons of the substantia nigra pars compacta,\textsuperscript{517} or to more widespread cell disappearance is diseases such as those mediated by prions (e.g. ref. 7 and 518). Note of course that LPS is actually used to induce a form of Parkinson’s disease in experimental animals.\textsuperscript{4,230–237}
Fig. 12 Some of the mechanisms of bacterial translocation from the intestine in a 'leaky gut', based on ref. 430. Some cells (and LPS) may pass through tight junctions, while others pass through Peyer's patches or through spaces vacated by dead cells whose death may be initiated by LPS. Diagram is not to scale.

Within the present framework, there are at least three general and straightforward explanations for this differentiation of diseases despite a broad common cause. The first is that (as with infectious diseases), the nature of the microorganisms differs, with some of these inflammatory diseases clearly being more associated with some microbes than are others (e.g. ref. 5, 43 and 64). The second is simply that the tissue location of the dormant bacteria differs. The third follows as much from our ignorance of the molecular details, as discussed above, as from what we know – namely the fact that we know little of the different effects of LPS type and concentration, and the effects of different levels of cytokines and other molecules that may themselves vary this. Sharpening these kinds of analyses will obviously feature as an important area for future research, and we rehearse the first two points briefly.

Differences in the organisms forming the dormant blood microbiome

We\textsuperscript{5} and others (e.g. ref. 36, 43, 48, 49, 52, 62, 64 and 519–522) have provided both (ultra)microscopic and molecular (sequence-based) evidence for a very great variety of culture-negative organisms that have been noted to be present in the blood, despite the fact that it is normally considered to be sterile.

Differences in the tissue locations of dormant bacteria

In a similar vein, microbes – presumably persistent, dormant organisms – are regularly detected in other tissues in which any degree of proliferation would be highly inimical to the host. Some recent examples involving just reproductive disorders include the vagina,\textsuperscript{523–525} the placenta,\textsuperscript{526–530} and the amniotic fluid,\textsuperscript{531–540} while recent evidence has also been provided for a sub-epidermal microbiome.\textsuperscript{541} The considerable evidence for a dormant CNS microbiome was discussed earlier, and we here note the presence in the brain of TLR4 and its major role in neurodegeneration,\textsuperscript{542} consistent with the idea that waking up dormant microbes can stimulate overt neurodegenerative disease.

A note on autoantibodies

A number of the diseases (e.g. rheumatoid arthritis, multiple sclerosis, psoriasis) for which we are invoking a microbial component involving LPS are usually considered to be autoimmune diseases. The question then arises as to the origins of this autoimmunity. If LPS were a protein with a defined structure it would be relatively easy to compare its epitope sequences with those of the targets of host antibodies in different circumstances (e.g. ref. 543–546), but of course it is not. This said, there is plenty of evidence that host autoantibodies are elicited by LPS that have less than perfect specificity for the immunogen (e.g. ref. 547–558), so while most of this work is not very recent, this question of LPS-induced antibody non-specificity seems an avenue well worth exploring. We note too the potential toxicity of exogenously administered anti-LPS antibodies.\textsuperscript{559,560} Regarding an autoimmune hypothesis, Marshall, Proal and colleagues highlight precisely this, along with a role for the vitamin D receptor.\textsuperscript{55,36,564–565}

Other hallmarks, and the role of iron dysregulation

While LPS itself as commonly measured seems to be a rather inadequate biomarker for chronic, inflammatory disease (Table 2), LBP (Table 1) and longer-lived markers of LPS exposure like IgM and IgA antibodies\textsuperscript{5,43,543–546,555–570} may be more promising.

What serves to wake up the dormant microbes is not yet clear, and it is unlikely to be a single element. One possibility is certainly host stress as reflected in noradrenaline levels, a mechanism championed with considerable evidence (at least in terms of stimulating the growth of Gram-negative organisms) by Lyte, Freestone and colleagues.\textsuperscript{515,222,571–579} We note that catecholamine synthesis may be induced in macrophages by LPS,\textsuperscript{580,581} and that catecholamines increase inflammation\textsuperscript{582,583} (another positive feedback loop). It is of special interest here that noradrenaline can act as an iron chelator,\textsuperscript{584–586} since iron is normally seen as the nutrient most limiting to bacterial growth \textit{in vivo} (e.g. ref. 16, 19–21 and 587–591). As we have pointed out before,\textsuperscript{6–10} the diseases highlighted here are precisely those where iron dysregulation, inflammation, coagulopathies, microparticles,\textsuperscript{592,593} and now a microbial component involving LPS \textit{sensu lato}, are seen to coexist.
Concluding remarks, areas of ignorance, and therapeutic potential

It is undoubtedly the case that despite our greatly improved understanding of many of the pathways involved in inflammation and sepsis (sensu lato), strategies for drug development have been noted mainly by their relative failure,\(^{411,594–597}\) probably in significant measure because they aim at individual targets (see ref. 297). As a systems problem, the way to improve our therapeutic strategies is to recognise that there are multiple targets or steps. We have here stressed that LPS (sensu lato) created by the resuscitation of dormant bacteria is likely heavily involved, and that the latter can be affected greatly by the concentrations of free iron (that may also be a target for therapy). Fig. 13 shows some of the various translocations of dormant and proliferating bacteria between the different tissues, and the various steps that might thus be targeted. Improving methods for quantitative lipidomics (e.g. ref. 598–603) are likely to be of considerable value here.

Here we have stressed the significance of LPS, but initially promising trials of an anti-LPS antibody (HA-1A, Centoxin)\(^{604}\) were not sustained (as is common\(^{605,606}\)) because of ineffectiveness\(^{607,608}\) or toxicity.\(^{559,560}\) This was probably because of its lack of specificity between lipid A and other hydrophobic ligands,\(^{609}\) and drug promiscuity is a function of hydrophobicity more generally (e.g. ref. 173, 468 and 610–612). Recognising that factor C, the active component of the Limulus amoebocyte lysate,\(^{61}\) necessarily binds to LPS, Ding, Wohland and colleagues have isolated so-called sushi peptides therefrom,\(^{613–620}\) in particular sushi peptides S1 and S3. These are 34mers that can bind to and inactivate endotoxin molecules (and are in some cases directly antibacterial), in concert with bacterial phospholipids.\(^{621}\)

They are said to have low human cell toxicity, and these peptides (or variants\(^{622,623}\)) would seem to have significant therapeutic potential. As a hydrophobic target, variant lipocalins binding LPS (‘anticalins’\(^{624–628}\)) might also be of value here. The evidence that HDL can bind to and sequester LPS was given above.

It is hard to gauge whether a better treatment than an anti-LPS antibody might involve recombinant LBP because while LBP can sequester LPS it can also transfer it to TLR4.\(^{127,134,629–631}\) Probably the best strategy is to avoid letting the bacteria proliferate in an uncontrolled manner at all, and to this end an iron-withholding strategy\(^{632}\) seems most suitable (e.g. ref. 6, 7 and 633–636) (and not a fortification one\(^{637,638}\)). In a similar vein, many of the substances found to be anti-inflammatory are so because of their iron-chelating properties (e.g. ref. 7 and 639–641), though clearly there are a vast number of possible steps (plural) at which anti-inflammatory substances may act. Those involving downstream cytokines (e.g. ref. 539) are outwith our scope here.

In addition, provided one can avoid excessive LPS shedding and a Jarisch–Herxheimer reaction,\(^{266,268}\) suitable antibiotics (e.g. minocycline\(^{442–450}\)) that have polypharmacological properties\(^{651,652}\) must certainly have a role in treating purportedly non-communicable inflammatory diseases, as well as those established as infectious. It is at least worthy of mention,\(^{653}\) albeit drugs can be quite promiscuous with regard to hitting multiple targets,\(^{173,466,651,652,654}\) that certain antibiotics are both used and effective in the treatment of diseases such as multiple sclerosis,\(^{655–661}\) rheumatoid arthritis,\(^{544,642,651,652,662–665}\) and psoriasis,\(^{666–668}\) while vaccination can also work to protect against supposedly non-communicable disease.\(^{669,670}\)

A modern trend is to use patients as their own controls (so-called \(n=1\)\(^{671}\) or \(n\)-of-1\(^{672,673}\) methods), in suitable crossover designs. These seem ideally suited to chronic diseases of the type discussed here, especially for those in which disease severity can itself change significantly (‘flare’\(^{674–677}\)) on quite rapid timescales (for the large and very numerous circadian changes in a mammalian transcriptome, see ref. 678). Indeed, we predict that such flares will be accompanied by major changes in the relevant microbiomes. But to understand the precise mechanisms involved we shall need much better, more quantitative, and above all reliable methods for measuring and manipulating the microbes, pathways and pathway elements involved. This is the most urgent task for the future.

Note added in proof

A recent and complementary article highlights the role of LPS translocation directly from the gut.\(^{679}\)

Acknowledgements

We thank Dr David Brough for commenting on the manuscript and Prof Ian Roberts for drawing our attention to the literature
on quiescent intracellular reservoirs. We thank the Biotechnology and Biological Sciences Research Council (grant BB/L025752/1) as well as the National Research Foundation (NRF) of South Africa for supporting this collaboration. This is also a contribution from the Manchester Centre for Synthetic Biology of Fine and Speciality Chemicals (SYNBIOCHEM) (BBSRC grant BB/M017702/1).

References


7 D. B. Kell, Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples, *Arch. Toxicol.*, 2010, **84**, 823–889.

8 D. B. Kell and E. Pretorius, Serum ferritin is an important disease marker, and is mainly a leakage product from damaged cells, *Metalomics*, 2014, **6**, 748–773.


63 G. J. Domingue, Demystifying pleomorphic forms in persistence and expression of disease: are they bacteria and is peptidoglycan the solution?, Discov. Med., 2010, 10, 234–246.


Integrative Biology


104 J. Y. Chien, J. S. Jerng, C. J. Yu and P. C. Yang, Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis, *Crit. Care Med.*, 2005, 33, 1688–1693.


of kidney disease in finnish patients with type 1 diabetes, Diabetes Care, 2009, 32, 1689–1693.


165 J. M. Bower, D. S. Eto and M. A. Mulvey, Covert operations of uropathogenic Escherichia coli within the urinary tract, Traffic, 2005, 6, 18–31.


173 D. B. Kell, P. D. Dobson, E. Bilsland and S. G. Oliver, The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so, *Drug Discovery Today*, 2013, 18, 218–239.


199 J. Miklossy, A. Kis, A. Radenovic, L. Miller, L. Forro, R. Martins, K. Reiss, N. Darbinian, P. Darekar, L. Mihaly


206 J. Miklossy, Chronic or late lyme neuroborreliosis: analysis of evidence compared to chronic or late syphilsis, Open Neurol. J., 2012, 6, 146–157.


286 Y. Li and A. Goldbeter, Pulsatile signaling in intercellular communication. Periodic stimuli are more efficient than random or chaotic signals in a model based on receptor desensitization, Biophys. J., 1992, 61, 161–171.


351 D. Lamarque, A. P. Moran, Z. Szepes, J. C. Delchier and B. J. Whittle, Cytotoxicity associated with induction of


440 H. Ashida, H. Mimuro, M. Ogawa, T. Kobayashi, T. Sanada, M. Kim and C. Sasakawa, Cell death and infection:


511 X. Han, M. P. Fink, R. Yang and R. L. Delude, Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice, Shock, 2004, 21, 261–270.


539 P. Y. Ng, D. J. Ireland and J. A. Keelan, Drugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birth, Front. Immunol., 2015, 6, 166.


545 A. Ebringer and T. Rashid, Rheumatoid arthritis is caused by a Proteus urinary tract infection, APeMS, 2014, 122, 363–368.


553 R. Dziarski, Comparison of in vitro and in vivo mitogenic and polyclonal antibody and autoantibody responses to


569 M. Maes, M. Kubera, J. C. Leunis and M. Berk, Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut, J. Affective Disord., 2012, 141, 55–62.


584 P. P. Freestone, M. Lyte, C. P. Neal, A. F. Maggs, R. D. Haigh and P. H. Williams, The mammalian neuroendocrine


614 N. S. Tan, B. Ho and J. L. Ding, High-affinity LPS binding domain(s) in recombinant factor C of a horseshoe crab neutralizes LPS-induced lethality, FASEB J., 2000, 14, 859–870.


618 S. Leptihn, L. Guo, V. Freer, B. Ho, J. L. Ding and T. Wohland, One step at a time: action mechanism of Sushi 1 antimicrobial peptide and derived molecules, Virulence, 2010, 1, 42–44.


620 P. Li, M. Sun, T. Wohland, D. Yang, B. Ho and J. L. Ding, Molecular mechanisms that govern the specificity of Sushi peptides for Gram-negative bacterial membrane lipids, Biochemistry, 2006, 45, 10554–10562.


636 C. Zeng, Q. Chen, K. Zhang, Q. Chen, S. Song and X. Fang, Hepatic Heparicin Protects against Polymicrobial Sepsis in Mice by Regulating Host Iron Status, Anesthesiology, 2015, 122, 374–386.


640 V. Chobot and F. Hadacek, Iron and its complexation by phenolic cellular metabolites: from oxidative stress to chemical weapons, Plant Signaling Behav., 2010, 5, 4–8.

641 V. Chobot, F. Hadacek and L. Kubicova, Effects of selected dietary secondary metabolites on reactive oxygen species production caused by iron(n) autoxidation, Molecules, 2014, 19, 20023–20033.


649 S. F. Abcouwer, C. M. Lin, S. Shankugam, A. Muthusamy, A. J. Barber and D. A. Antonetti, Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury, *J. Neuroinflammation*, 2013, 10, 149.


668 A. A. Alzolibani and K. Zedan, Macrolides in Chronic Inflammatory Skin Disorders, *Mediators Inflammation*, 2012, 159354.


